Celgene's oral cancer drug gets EU panel recommendation

March 23 (Reuters) - Celgene Corp. (CELG.O) said the European Medicines Agency has recommended the company's oral cancer drug in a combination therapy for multiple myeloma patients who have received at least one treatment earlier.

The recommendation is for use of the drug, Revlimid, in combination with dexamethasone, the company said in a statement.

(Reporting by Hari Kumar in Bangalore)

((Editing by Anil Kumar; Reuters Messaging: hari.kumar.reuters.com@reuters.net; within U.S. +1 646 223 8780; outside U.S. +91 80 4135 5800 )) Keywords: CELGENE DRUG/

(C) Reuters 2007. All rights reserved. Republication or redistribution ofReuters content, including by caching, framing or similar means, is expresslyprohibited without the prior written consent of Reuters. Reuters and the Reuterssphere logo are registered trademarks and trademarks of the Reuters group ofcompanies around the world.nWNAS4824